Unione Europea - italiano - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabete mellito, tipo 2 - farmaci usati nel diabete - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , triplice terapia di associazione) in aggiunta alla dieta e all'esercizio fisico in pazienti non adeguatamente controllati il loro dosaggio massimo tollerato di metformina ed una sulfonilurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sun pharmaceutical industries (europe) b.v. - pemetrexed - pemetrexed

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sun pharmaceutical industries (europe) b.v. - citalopram - citalopram

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sun pharmaceutical industries (europe) b.v. - oxaliplatino - oxaliplatino

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sun pharmaceutical industries (europe) b.v. - acido zoledronico - acido zoledronico

Unione Europea - italiano - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - teriparatide - osteoporosis; osteoporosis, postmenopausal - omeostasi del calcio - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Unione Europea - italiano - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - atosiban (as acetate) - nascita prematura - altre gynecologicals - atosiban è indicato per ritardare l'imminente nascita pre-termine in stato di gravidanza, le donne adulte con:regolare le contrazioni uterine di almeno 30 secondi di durata, ad un tasso di ≥ 4 per 30 minuti;una dilatazione cervicale da 1 a 3 cm (0-3 per nulliparas) e appianamento di ≥ 50%;età di gestazione dalle 24 fino a 33 settimane complete;una normale frequenza cardiaca fetale.

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sun pharmaceutical industries (europe) b.v. - sumatriptan - sumatriptan

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sun pharma italia srl - venlafaxina - venlafaxina

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sun pharma italia srl - valsartan - valsartan